Efficacy and safety of pembrolizumab-lenvatinib in metastatic endometrial cancer: results from the French multicenter early access program.
BACKGROUND Pembrolizumab-lenvatinib (P/L) is a standard option for patients with advanced or metastatic endometrial cancer (a/m EC) progressing after platinum-based chemotherapy, based on the KEYNOTE-775 trial. However, concerns remain regarding its real-world applicability, particularly in older, frailer patients and...